The Polish manuscript can also be published in an English version. The journal does not provide translation services. Manuscripts that are not properly prepared will be returned to the authors for correction. If the author fails to introduce corrections, the article will be removed from the system after 30 days.

Large Language Models (LLMs), such as ChatGPT, do not currently meet our authorship criteria. The attribution of authorship involves taking responsibility for the submitted work, which cannot be effectively done in the case of LLMs. The use of LLMs should be adequately documented in the Methods section (or, if the Methods section is not available, in an appropriate alternative section) of the manuscript.

• title of the paper both in Polish and English (the title should be concise and informative);
• abstract both in Polish and English;
•  keywords both in Polish and in English.

All other data are provided by the authors in the editorial system (do not include them in the manuscript file).

• Research’s subject;
• Purpose;
• Material and methods;
•  Results;
• Conclusions.

MAIN BODY OF THE MANUSCRIPT

• Abstract: structured, in Polish and English;
• Keywords: in Polish and English;
• What does this manuscript add to the subject literature:
  • 2–5 bulleted points/statements,
  • indicate the impact of research findings on patients/pharmacy/clinical practice, etc.

• Introduction;
• Purpose of the manuscript: here specific objective(s) and a priori hypotheses should be stated;
• Bioethic/Ethics Committee Approval: authors conducting a study involving humans or animals should include a statement confirming that they obtained approval (or a waiver of thereof) granted by the appropriate institutional and/or national research ethics committee.

• Methodology: must be detailed enough to evaluate the study as high quality. It should contain an appropriate statistical analysis (if applicable) and provide strong sides of the manuscript.
• Results: should not duplicate the results presented in tables, graphs, pictures, and text;
• Discussion: should include:
  • a brief summary of the main findings;
  •  strengths and weaknesses of the study;
  • identification of important differences in results;
  • significance of the study (including possible explanations and implications for clinicians and policymakers)
  • and a commentary on unanswered questions and future research;
• Conclusions;
• Acknowledgment: if applicable;
• Sources of funding: if applicable;
• Conflict of interest statement;
• References: up to 40.

• Abstract: structured, in Polish and English;

• Keywords: in Polish and English;
• What does this manuscript add to the subject literature:
  • 2–5 bulleted points/statements;
  • indicate the impact of research findings on patients/pharmacy/clinical practice, etc.

• Introduction;
• Purpose of the manuscript: here specific objective(s) and a priori hypotheses should be stated;
• Bioethic/Ethics Committee Approval: authors conducting a study involving humans or animals should include a statement confirming that they obtained approval (or a waiver of thereof) granted by the appropriate institutional and/or national research ethics committee. 

• Methodology;
• Results;
• Discussion: should include:
  • a brief summary of the main findings;
  • strengths and weaknesses of the study and strengths and weaknesses in comparison to other studies;
  •  identification of important differences in results;
  •  significance of the study (including possible explanations and implications for clinicians and policymakers)
  • and a commentary including unanswered questions and future research;
• Conclusions;
• Acknowledgments: if applicable;
• Funding Sources: if applicable;
• Conflict of interest statement;
• References: up to 15.

• Keywords: in Polish and English;
• What does this manuscript add to the subject literature:
  • 2–5 bulleted points/statements;
  • indicate the impact of research findings on patients/pharmacy/clinical practice, etc.

• Introduction;
• Purpose of the paper;
• Methodology of literature search and source selection;
• Results;
• Discussion: should include:
  • a brief summary of the main findings;
  • strengths and weaknesses of the study and strengths and weaknesses in comparison to other studies;
  • identification of important differences in results;
  • significance of the study (including possible explanations and implications for clinicians and policymakers) and a commentary including unanswered questions and future research;
• Conclusions;
• Acknowledgments: if applicable;
• Sources of funding: if applicable;
• Conflict of interest statement;
• References: up to 60.

Commentary

Commentaries are short articles conveying thoughts, reflections, and opinions or addressing issues found in previously published articles in Farmacja Polska. Commentaries are not for publishing original research or data. Reviewing comments is at the discretion of the editors. The text should contain no more than 10,000 characters with spaces, excluding abstracts and references.

Tables, charts/figures (a maximum of 2 altogether) should be placed at the end of the manuscript after the references. They should have captions in Polish and in English. Their place should be marked in the main text.

The commentary should include the following section headings:

• Abstract: unstructured, in Polish and English;
• Keywords: in Polish and English;
• Commentary text: unstructured;
• Acknowledgments: if applicable;
• Sources of funding: if applicable;
• Conflict of interest statement
• References: up to 10

TEXT FORMATTING

• preferred file type: Rich Text Format (*.rtf);
• any Microsoft Word editor format (*.doc, *.docx), not password protected for reading.

Use a common font (e.g., Times New Roman or Calibri).

Use bold or italics only in subtitles, Latin names, and chemical compound names.

Use the automatic page numbering function to number pages.

Do not use the field function.

For indentation, use tabs or other commands, not spaces.

First, second, and third row headings should be clearly distinguishable; however, they should not be numbered. Do not use more than third row headers.

Use table functions, not spreadsheets, to create tables.

For equations, use an equation editor or the MathType tool.

References to literature, figures, and tables should be placed in the order of their appearance in the text.

Only international drug names should be used in the text.

Laboratory values should be expressed using the International System of Units (SI). Always use international characters and symbols (SI units).

Numbers should be written in Arabic numerals. Do not start a sentence with a digit; numbers at the beginning of a sentence should always be spelled out.

Headings – please use no more than three levels of displayed headings.

Abbreviations – abbreviations should be defined at their first mention, and then used consistently. It is acceptable to include a glossary of abbreviations at the beginning of the manuscript, after keywords.

Footnotes – footnotes provide additional information that could disrupt the flow of the main text. They can include references; however, they should not be limited to them, and they should never include their bibliographic details. They should also not include any figures or tables.

Footnotes to the text are numbered consecutively; those in tables should be indicated by superscript lowercase letters (or asterisks for significance values and other statistics). Footnotes to the title and authors of the article should not be marked with cross-reference symbols.

Use footnotes instead of endnotes.

• original articles – 40;
• review articles – 60;
• short communications - 15;
• commentaries - 10;
• case reports-20.

• in the case of up to four authors, give the last names and initials of the first name of all authors;
• if there are five or more authors, give the last names and name initials of the first three authors and add "et al.".

When stating the page range, use a semi-pause, which is longer in the notation (without spaces between the page numbers and the semi-pause). The name of the journal, written in italics, is followed by the year of publication, semicolon, space, volume, notebook (in parentheses), colon, space, and full page range, e.g., 155–159 (not: 155–9).

EXAMPLES:

1. Smeeth L, Iliffe S. Community screening for visual impairment in the elderly. Cochrane Database Syst Rev. 2002; (2):CD001054. doi: 10.1002/14651858.
2. Duchin JS. Can preparedness for biological terrorism save us from pertussis? Arch Pediatr Adolesc Med. 2004; 158(2): 106–107. Dostępny w internecie: http://archpedi.jamanetwork.com.ezproxy1.­library.arizona.edu/article.aspx?articleid=485611. Dostęp 9.07.2014.

• employment,
• consulting,
• stock ownership,
• honoraria,
• paid expertise,
• patents or patent applications,
• travel grants/grants.

ACCEPTABLE FILE FORMATS

• preferred file type: Rich Text Format (*.rtf);
• any Microsoft Word editor format (*.doc, *.docx), not password protected for reading.

• Tables in any version of MS Word.

• EPS or PDF files;

• chart files in any version of MS Word.

• TIFF/PSD – with flattened text layers and without matching layers (300 ppi resolution at 1:1 size);
• Composite PDF – from any program, as long as the fonts are embedded (300 ppi resolution at 1:1 size);:
• EPS – from any program, as long as there are cursive fonts;
• JPG (JPG images use a lossy compression algorithm that reduces file sizes by discarding some of the less important or redundant information in an image). Set the JPG quality parameter (resolution of 300 ppi in 1:1 size) to "minimum compression, maximum quality".

• significant contribution to the conceptualization or design of the manuscript or data acquisition, analysis, or interpretation;
• development of the manuscript or critical revision of important intellectual content;
• final approval of the version to be published.